HI

Analyst Note: Hillenbrand, Inc. (HI)

Date: 2026-06-13 Current Price: $31.98

1. Structural Readiness

State: Context-Only Current Price: $31.98 Extension: — ATR Current: 0.2% (Sub-threshold)

Analysis:

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Exposure: None Named

There is no named macro or secular thesis attached to HI at this specific date. The investment case is strictly TACTICAL, driven by the quality of the technical setup and the immediate business fundamentals rather than a broad thematic tailwind. The conviction must be derived entirely from the structural integrity of the chart pattern and the strength of the company's operational guidance, without inventing external narratives.

3. Business Overview

Hillenbrand, Inc. operates as a diversified industrial enterprise with global operations, structured into three primary divisions: Advanced Process Solutions, Molding Technology Solutions, and Batesville.

• Advanced Process Solutions: Designs and manufactures specialized process and material handling equipment, including compounding, extrusion, and screening/separating technologies. This segment serves plastics, food, pharmaceuticals, chemicals, and energy sectors.
• Molding Technology Solutions: Provides injection molding and extrusion apparatus, hot runner systems, and mold bases. Key end markets include automotive, consumer goods, medical, and packaging.
• Batesville: A funeral service division focused on the design and sale of funeral products and solutions.

Operational Evidence (as of 2025-08-12): Management provided specific guidance updates and operational metrics in the August 2025 earnings transcript, which remain the most recent primary data points available as of June 2026:

• Backlog: The total backlog stood at $1.57 billion, a decrease of 10% year-over-year, which management noted was "as expected."
• Guidance: Management raised the revenue guidance range to $2.59 billion – $2.63 billion (previously $2.56B–$2.62B) and narrowed the adjusted EPS range to $2.20 – $2.35 (previously $2.10–$2.45), maintaining the midpoint.
• Cash Flow & CapEx: Full-year operating cash flow is expected to be approximately $60 million, with $40 million in expected capital expenditures. Management emphasized prioritizing projects related to "in region, for region" initiatives.
• Order Wins: Key order wins in late July provided "greater line of sight" to achieve full-year expectations.
• Segment Growth: The "growing and less cyclical" end market (likely Batesville or specific Molding segments) now represents >25% of global revenue.
• Cross-Selling: The company reported $40 million in sales to date from cross-selling initiatives.
• Pro Forma Backlog: The Advanced Process Solutions pro forma backlog increased 7% year-over-year to $55 million, driven by demand for hot runner and mold-based components.

4. Archetype and Conviction

Archetype: Growth Leader Rationale: The company fits the "Growth Leader" archetype based on its ability to narrow guidance ranges upward, report positive order wins, and successfully execute cross-selling strategies that are expanding its revenue mix. The shift toward a "less cyclical" end market (representing >25% of revenue) suggests a structural improvement in earnings quality.

Valuation & Financial Spine:

• Forward Consensus EPS (FY1): $2.5763
• Forward Consensus EPS (FY2): $2.60
• Current Price: $31.98
• Implied P/E (FY1): ~12.4x

Conviction Stack:

• Thesis Strength: Low (Tactical only; no macro thesis).
• Evidence Quality: High. Management has provided specific, updated guidance and clear metrics on backlog and cash flow.
• Structural Quality: Moderate. The setup is "Forming," meaning the structure is present but unconfirmed. The low ATR (0.2%) suggests the market is currently in a consolidation phase with low volatility, which is typical for a forming coil but lacks the momentum of a confirmed breakout.
• Setup Readiness: Partial. The price is holding above support, but the breakout has not fired.
• Rerating Potential: Moderate. The narrowing of the EPS guidance range and the shift toward less cyclical revenue streams provide a fundamental basis for a multiple expansion *if* the technical breakout confirms the trend.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Fundamental: Confirmation that the "in region, for region" CapEx projects are yielding accelerated order intake or margin expansion in the next quarterly report.
• Guidance: Management raising the midpoint of the FY2026 guidance range further, indicating the $2.59B–$2.63B range was conservative.

What Would Invalidate the Case:

• Fundamental: A significant miss on the $60 million operating cash flow target or a failure to execute the $40 million CapEx plan, suggesting liquidity or execution issues.
• Backlog: A further decline in the $1.57 billion backlog that exceeds the "expected" 10% decrease, signaling a loss of visibility.

Evidence Gaps:

• Missing Evidence: There is no specific data available between the August 2025 earnings call and the current date (June 2026) regarding interim quarterly performance, specific margin trends, or the exact execution status of the "in region, for region" projects. The analysis relies heavily on the August 2025 guidance as the most recent anchor.
• Missing Evidence: No specific data on the current backlog composition or the exact revenue contribution of the "less cyclical" segment as of June 2026.

PRIVATE ANALYST CALL

Judgment: Hold Confidence: medium Key risks: Technical setup is unconfirmed (Forming coil, no breakout fired); Current ATR of 0.2% is sub-threshold indicating low momentum; Backlog decreased 10% YoY to $1.57B; Lack of named secular thesis limits rerating catalysts. Sizing hint: Position size should be minimal or zero until a confirmed breakout occurs; do not size based on the forming state alone. Expected path: Management expects to achieve full-year guidance with $60M operating cash flow and $40M CapEx; structural implication is a potential breakout if order wins continue to support the backlog. Expected horizon: 3 to 6 months for the forming coil to resolve into a confirmed breakout or invalidation.